Discovery

Antabio has strong expertise in antibacterial discovery, with a particular focus on the identification and progression of novel chemical entities against new and clinically relevant bacterial targets. Leveraging integrated capabilities in medicinal chemistry, microbiology, and early ADMET profiling, Antabio is well positioned to advance hit-to-lead and lead optimization programs and to identify novel preclinical candidates addressing unmet needs in drug-resistant Gram-negative infections. This expertise is further strengthened through its collaboration with the Global Antibiotic Research and Development Partnership (GARDP), combining complementary scientific resources to accelerate the discovery of innovative compounds with new mechanisms of action and a clear path toward preclinical development.